These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31311364)

  • 1. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK.
    Bain SC; Bekker Hansen B; Hunt B; Chubb B; Valentine WJ
    J Med Econ; 2020 Jan; 23(1):98-105. PubMed ID: 31311364
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States.
    Ali SN; Dang-Tan T; Valentine WJ; Hansen BB
    Adv Ther; 2020 Feb; 37(2):869-882. PubMed ID: 31925649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in Denmark.
    Lindvig A; Tran MP; Kidd R; Tikkanen CK; Gæde P
    Curr Med Res Opin; 2021 Jun; 37(6):949-956. PubMed ID: 33729871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia.
    Alluhidan M; Alturaiki A; Alabdulkarim H; Aljehani N; Alghamdi EA; Alsabaan F; Alamri AA; Malkin SJP; Hunt B; Alhossan A; Al-Jedai A
    Adv Ther; 2024 Nov; 41(11):4140-4152. PubMed ID: 39261418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.
    Pollock RF; Muduma G; Valentine WJ
    Diabetes Obes Metab; 2013 Feb; 15(2):121-9. PubMed ID: 22882321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
    Ren H; Berry S; Malkin SJP; Hunt B; Bain S
    BMJ Open; 2023 Sep; 13(9):e070473. PubMed ID: 37775297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?
    Herman WH; Braffett BH; Kuo S; Lee JM; Brandle M; Jacobson AM; Prosser LA; Lachin JM
    J Diabetes Complications; 2018 Oct; 32(10):911-915. PubMed ID: 30082172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
    Dempsey M; Mocarski M; Langer J; Hunt B
    J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving management of glycaemic control in people with T2DM in primary care: estimation of the impact on the clinical complications and associated costs.
    Mata-Cases M; Mahon J; Mauricio D; Franch-Nadal J; Real J; Hex N
    BMC Health Serv Res; 2020 Aug; 20(1):803. PubMed ID: 32847581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control.
    Seinfeld J; Sobrevilla A; Rosales ML; Ibáñez M; Ruiz D; Penny E; Londoño S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):661-669. PubMed ID: 38584495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study).
    Laiteerapong N; Ham SA; Gao Y; Moffet HH; Liu JY; Huang ES; Karter AJ
    Diabetes Care; 2019 Mar; 42(3):416-426. PubMed ID: 30104301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
    Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
    Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.
    Valentine WJ; Curtis BH; Pollock RF; Van Brunt K; Paczkowski R; Brändle M; Boye KS; Kendall DM
    Diabetes Res Clin Pract; 2015 Jul; 109(1):95-103. PubMed ID: 25989713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the direct health and indirect societal costs of diabetes in the UK using a cost of illness model.
    Hex N; MacDonald R; Pocock J; Uzdzinska B; Taylor M; Atkin M; Wild SH; Beba H; Jones R
    Diabet Med; 2024 Sep; 41(9):e15326. PubMed ID: 38890775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Analysis of Therapeutic Inertia in Type 2 Diabetes Management Across a Diverse Population of Health Care Organizations in the USA.
    Rattelman CR; Ciemins EL; Stempniewicz N; Mocarski M; Ganguly R; Cuddeback JK
    Diabetes Ther; 2021 Feb; 12(2):581-594. PubMed ID: 33460018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit.
    Baxter M; Hudson R; Mahon J; Bartlett C; Samyshkin Y; Alexiou D; Hex N
    Diabet Med; 2016 Nov; 33(11):1575-1581. PubMed ID: 26773733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data.
    Hellgren M; Svensson AM; Franzén S; Ericsson Å; Gudbjörnsdottir S; Ekström N; Bertilsson R; Valentine W; Malkin S
    Diabetes Obes Metab; 2021 Jul; 23(7):1604-1613. PubMed ID: 33729661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.